Article thumbnail

Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients

By Gianmaria Baldin, Arturo Ciccullo, Stefano Rusconi, Amedeo Capetti, Gaetana Sterrantino, Manuela Colafigli, d&apos, Andrea Giacometti, Maria Vittoria Cossu, Alberto Borghetti, William Gennari, Cristina Mussini, Vanni Borghi and Simona Di Giambenedetto


Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir (3TC+DTG) could be an effective and tolerated option for simplification in human immunodeficiency virus (HIV)-1-positive patients

Topics: ART, Dolutegravir, HIV, Lamivudine, Simplification, Two-drug regimen
Publisher: 'Elsevier BV'
Year: 2019
DOI identifier: 10.1016/j.ijantimicag.2019.09.002
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.